Procept Biorobotics Corp
PRCT
View Detailed Chart
26.360USD
+1.290+5.15%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.15%
5 Days
+2.21%
1 Month
+16.17%
6 Months
-28.10%
Year to Date
-16.21%
1 Year
-57.32%
View Detailed Chart
TradingKey Stock Score of Procept Biorobotics Corp
Currency: USD Updated: 2026-03-26Key Insights
Procept Biorobotics Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 47 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.92.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Procept Biorobotics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Procept Biorobotics Corp Highlights
StrengthsRisks
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 126.19% year-on-year.
Overvalued
The company’s latest PE is -14.57, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 59.92M shares, decreasing 3.28% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.34K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.66.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
32.917
Target Price
+31.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Procept Biorobotics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Procept Biorobotics Corp Info
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Ticker SymbolPRCT
CompanyProcept Biorobotics Corp
CEOWood (Larry L)
Websitehttps://www.procept-biorobotics.com/
Related Instruments
-3.37%
-1.76%
-3.17%
-0.55%
-3.39%
-3.47%
-1.58%
-1.43%
-2.67%
-0.60%
-1.55%
-1.75%
-3.72%
-2.61%
-2.01%
-3.36%
-2.86%
-1.52%
-0.91%
-1.82%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
66184.680
+193.920 (+0.29%)
275.340
+1.990 (+0.73%)
1988.680
+5.140 (+0.26%)
361.830
-10.280 (-2.76%)
4492.520
+112.460 (+2.57%)
100.609
+7.287 (+7.81%)
1.151
-0.002 (-0.17%)
160.252
+0.465 (+0.29%)
